Institution Directory

Clinical trials at Dana-Farber Cancer Institute

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1325

Shown on this page

Current sort

Live official records

Conditions: Bladder Cancer, Cystectomy
Interventions: Exercise Training, Nutritional Intervention; Other · Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Blood collection for GDF-15; Other
Lead sponsor: Breast Cancer Trials, Australia and New Zealand; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Newly Diagnosed and Recurrent Glioblastoma
Interventions: [177Lu]Lu-NeoB, [68Ga]Ga-NeoB, Temozolomide; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Pembrolizumab; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • Mineola, New York • New York, New York + 2 more

Conditions: Lymphoma
Interventions: Rituximab, Methotrexate, Procarbazine, Temozolomide, Liso-cel, Fludarabine, Cyclophosphamide, Calcium folinate; Drug · Biological
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Aurora, Colorado • Tampa, Florida • Chicago, Illinois + 11 more

Conditions: Rectal Cancer, Colorectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
Interventions: Prehabilitation Program; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Venetoclax, Obinutuzumab, Acalabrutinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Leukemia, Myelodysplastic Syndrome
Interventions: AZD6738; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri

Conditions: Brain Metastases
Interventions: Whole brain radiation, Stereotactic radiation (SRS); Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hemophilia A
Interventions: Efanesoctocog Alfa BIVV001; Drug
Lead sponsor: Sanofi; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Gilbert, Arizona • Loma Linda, California • Los Angeles, California + 23 more

Conditions: Acute Myelogenous Leukemia
Interventions: DC/AML fusion cells; Biological
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Interventions: azenosertib; Drug
Lead sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more

About this Dana-Farber Cancer Institute institution page

What this page lists: ClinicalTrials.gov records that list Dana-Farber Cancer Institute in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Dana-Farber Cancer Institute

Filter and sort this campus

Live official records

Patient-Centered Surgical Prehabilitation

GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

AZD6738 for Patients With Progressive MDS or CMML

Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

About this Dana-Farber Cancer Institute institution page